Cefadroxil
NDC Package 63304-974-01
Package Information
Cefadroxil is a medication used to treat a wide variety of bacterial infections. Marketed by Ranbaxy Pharmaceuticals Inc., this product is identified by NDC 63304-974 and is authorized under FDA application ANDA065115.
Identification & Billing
- RxCUI: 105170 - cefadroxil 25 MG/ML Oral Suspension
- RxCUI: 105170 - cefadroxil (as cefadroxil monohydrate) 25 MG/ML Oral Suspension
- RxCUI: 105170 - cefadroxil 125 MG per 5 ML Oral Suspension
- RxCUI: 105171 - cefadroxil 500 MG in 5 mL Oral Suspension
- RxCUI: 105171 - cefadroxil 100 MG/ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63304 - Ranbaxy Pharmaceuticals Inc.
- 63304-974 - Cefadroxil
- 63304-974-01 - 75 mL in 1 BOTTLE
- 63304-974 - Cefadroxil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (63304-974). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63304-974-01 identifies a specific commercial package of 75 ml in 1 bottle of Cefadroxil, labeled by Ranbaxy Pharmaceuticals Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 75 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ranbaxy Pharmaceuticals Inc. on August 30, 2005. The current certification is valid through December 31, 2017.
What are the primary indications for this medication?
This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
How is this Ranbaxy Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63304097401. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 75 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
